Product
Supplier
Encyclopedia
Inquiry
Home > Encyclopedia > Epristeride

Epristeride

pharmaceutical raw materials
Epristeride structure

Epristeride 

structure
  • CAS No:

    119169-78-7

  • Formula:

    C25H37NO3

  • Chemical Name:

    Epristeride

  • Synonyms:

    Androsta-3,5-diene-3-carboxylic acid,17-[[(1,1-dimethylethyl)amino]carbonyl]-,(17β)-;(17β)-17-[[(1,1-Dimethylethyl)amino]carbonyl]androsta-3,5-diene-3-carboxylic acid;SKF 105657;17β-(tert-Butylcarbamoyl)androsta-3,5-diene-3-carboxylic acid;Epristeride;N-tert-Butylandrosta-3,5-diene-17β-carboxamide-3-carboxylic acid;ONO 9302

  • Categories:

    Active Pharmaceutical Ingredients  >  Urinary System Drugs

Description

Epristeride is a novel 5α-reductase inhibor.


Epristeride is a steroid acid.

Epristeride Basic Attributes

399.57

399.57

39517A04PS

DTXSID9048643

Characteristics

66.40000

5.49190

1.13±0.1 g/cm3(Predicted)

242-249 °C

596.0±50.0 °C(Predicted)

314.3ºC

1.563

206.6 Ų [M+H]+ [CCS Type: DT, Method: single field calibrated]

Drug Information

Drugs that inhibit 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE. They are commonly used to reduce the production of DIHYDROTESTOSTERONE. (See all compounds classified as 5-alpha Reductase Inhibitors.)

17-N-t-butylcarboxamide androst-3,5-diene-3-carboxylic acid

Epristeride Use and Manufacturing

Inhibitor (alpha reductase.

Computed Properties

Molecular Weight:399.6
XLogP3:5.1
Hydrogen Bond Donor Count:2
Hydrogen Bond Acceptor Count:3
Rotatable Bond Count:3
Exact Mass:399.27734404
Monoisotopic Mass:399.27734404
Topological Polar Surface Area:66.4
Heavy Atom Count:29
Complexity:788
Defined Atom Stereocenter Count:6
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes

Drug Function and Efficacy

Epristeramide is a new type of anti-competitive 5alpha-reductase inhibitor, which can form a ternary complex with 5alpha-reductase and NADF, thereby inhibiting the conversion of testosterone into dihydrotestosterone and reducing the water content of dihydrotestosterone in the prostate, leading to the atrophy of the hyperplastic prostate, thus achieving the purpose of treating prostate hyperplasia.

This ingredient has been used in drugs with the following functions (note: it does not mean that the ingredient itself has the following health functions)

Related Drugs

Registered Holders

  • Jiangsu Lianhuan Pharmaceutical Co., Ltd.

    China China
    Active

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.